Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 4/2024

Open Access 23-01-2024 | Trigeminal Neuralgia | Uncommon and/or Unusual Headaches and Syndromes (F Cohen, Section Editor)

Trigeminal Postherpetic Neuralgia: From Pathophysiology to Treatment

Authors: Christy S. Niemeyer, Michael Harlander-Locke, Andrew N. Bubak, Rachael Rzasa-Lynn, Marius Birlea

Published in: Current Pain and Headache Reports | Issue 4/2024

Login to get access

Abstract

Purpose of Review

Trigeminal postherpetic neuralgia (TG-PHN) is a neuropathic pain condition complicating herpes zoster (HZ) attributed to the trigeminal nerve. It poses significant challenges due to its persistent and debilitating nature. This review explores the clinical characteristics of TG-PHN, analyzes its pathophysiological underpinnings, and addresses existent and potential therapies.

Recent Findings

TG-PHN is one of the most common and complex PHN locations. It has distinguishing clinical and pathophysiological characteristics, starting with viral triggered injuries to the trigeminal ganglion (TG) and peripheral tissue and involving the ascending and descending brain modulation pathways. Current therapies include vaccines, oral and topical medications, and interventional approaches, like nerve blocks and neurostimulation.

Summary

This review covers TG-PHN’s clinical and physiological components, treatment options, and potential future targets for improved management. By exploring the complexities of this condition, we aim to contribute to developing more effective and targeted therapies for patients suffering from trigeminal PHN.
Literature
1.
Gershon A, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1(15016):2015.
2.
Thompson RR, et al. Herpes zoster and postherpetic neuralgia: changing incidence rates from 1994 to 2018 in the United States. Clin Infect Dis. 2021;73(9):e3210–7.PubMedCrossRef
3.
Tsau P-W, et al. Clinical presentations and outcome studies of cranial nerve involvement in herpes zoster infection: a retrospective single-center analysis. J Clin Med. 2020;9(4):946.PubMedPubMedCentralCrossRef
4.
5.
Borkar DS, et al. Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study. Ophthalmology. 2013;120(3):451–6.PubMedCrossRef
6.
Sadosky A, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8(1):45–56.PubMedCrossRef
7.
Orofacial T. International classification of orofacial pain, (ICOP). Cephalalgia. 2020;40(2):129–221.CrossRef
8.
9.
ICHD. Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
10.
Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines. J Infect Dis. 2021;224(12 Suppl 2):S429–42.
11.
Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.
12.
Pappagallo M, et al. Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms. Anesthesiology. 2000;92(3):691–8.PubMedCrossRef
13.
Gilden DH, et al. Neurologic complications of the reactivation of varicella–zoster virus. N Engl J Med. 2000;342(9):635–45.PubMedCrossRef
14.
15.
Harding S, Lipton J, Wells J. Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement. Br J Ophthalmol. 1987;71(5):353–8.PubMedPubMedCentralCrossRef
16.
• Park C, et al. The relative frequency of pruritus in postherpetic neuralgia patients presenting to the pain clinic and associative factors. Medicine (Baltimore). 2022;101(35):e30208. Paper investigating rarely studied but pathophysiologically relevant, postherpetic pruritus in patients with PHN.
17.
18.
19.
Nithyanandam S, et al. Eruption severity and characteristics in herpes zoster ophthalmicus: correlation with visual outcome, ocular complications, and postherpetic neuralgia. Int J Dermatol. 2009;48(5):484–7.PubMedCrossRef
20.
Zhou H, et al. A systematic review and meta-analysis of independent risk factors for postherpetic neuralgia. Ann Palliat Med. 2021;10(12):12181–9.PubMedCrossRef
21.
Fujiwara A, et al. Correlation between pain catastrophizing in acute herpes zoster and postherpetic neuralgia: a retrospective analysis. J Anesth. 2023.
22.
Drago F, et al. Acute pain and postherpetic neuralgia related to varicella zoster virus reactivation: comparison between typical herpes zoster and zoster sine herpete. J Med Virol. 2019;91(2):287–95.PubMedCrossRef
23.
Mahalingam R, et al. Persistence of varicalla-zoster virus DNA in elderly patients with postherpetic neuralgia. J Neurovirol. 1995;1(1):130–3.PubMedCrossRef
24.
Bubak AN, et al. Zoster-associated prothrombotic plasma exosomes and increased stroke risk. J Infect Dis. 2022.
25.
26.
Kleinschmidt-DeMasters B, Gilden DH. Varicella-zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med. 2001;125(6):770–80.PubMedCrossRef
27.
Prakash S, Dave A, Joshi H. Herpes zoster ophthalmicus evolving into headache characterised as hemicrania continua. BMJ Case Rep. 2018;2018.
28.
29.
•• Rehm S, et al. Sensory symptom profiles differ between trigeminal and thoracolumbar postherpetic neuralgia. Pain Rep. 2018;3(1):e636. Paper investigating the distinct sensory symptom profiles of patients with trigeminal PHN compared to those with PHN in the thoracolumbar region.
30.
Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and cutaneous deafferentation after facial shingles. Pain. 2002;96(1–2):9–12.PubMedCrossRef
31.
32.
Caccavale S, Caccavale T, La Montagna M. Post herpes zoster trigeminal trophic syndrome in a child: an example of immunocompromised district. Indian J Dermatol. 2016;61(1):124.PubMedPubMedCentralCrossRef
33.
Kodama-Takahashi A, et al. Neurotrophic keratopathy after trigeminal nerve block for treatment of postherpetic neuralgia. Case Rep Ophthalmol Med. 2018;2018:6815407.PubMedPubMedCentral
34.
Schlereth T, et al. Association between pain, central sensitization and anxiety in postherpetic neuralgia. Eur J Pain. 2015;19(2):193–201.PubMedCrossRef
35.
Cao X, et al. A meta-analysis of randomized controlled trials comparing the efficacy and safety of pregabalin and gabapentin in the treatment of postherpetic neuralgia. Pain Ther. 2023;12(1):1–18.MathSciNetPubMedCrossRef
36.
Alvarez FK, et al. Evaluation of the sensation in patients with trigeminal post-herpetic neuralgia. J Oral Pathol Med. 2007;36(6):347–50.PubMedCrossRef
37.
Truini A, et al. Pathophysiology of pain in postherpetic neuralgia: a clinical and neurophysiological study. Pain. 2008;140(3):405–10.PubMedCrossRef
38.
Hevner R, et al. An unusual cause of trigeminal-distribution pain and tumour. Lancet Neurol. 2003;2(9):567–71.PubMedCrossRef
39.
40.
Yoshida S, et al. Involvement of the spinal trigeminal nucleus secondary to herpes zoster in a patient with hemifacial redness and swelling. J Cutan Immunol Allergy. 2022;5(6):238–9.
41.
42.
• Li H, et al. Deficits in ascending and descending pain modulation pathways in patients with postherpetic neuralgia. Neuroimage. 2020;221:117186. Study providing valuable insights into the mechanisms underlying PHN, using imaging and clinical correlations.
43.
Laing KJ, et al. Immunobiology of varicella-zoster virus infection. J Infect Dis. 2018;218(suppl_2):S68–74.
44.
Bubak AN, et al. Varicella zoster virus differentially alters morphology and suppresses proinflammatory cytokines in primary human spinal cord and hippocampal astrocytes. J Neuroinflammation. 2018;15(1):318.PubMedPubMedCentralCrossRef
45.
Niemeyer CS, et al. VZV infection of primary human adrenal cortical cells produces a proinflammatory environment without cell death. Viruses. 2022;14(4)
46.
Como CN, et al. Varicella zoster virus induces differential cell-type specific responses in human corneal epithelial cells and keratocytes. Invest Ophthalmol Vis Sci. 2019;60(2):704–11.PubMedPubMedCentralCrossRef
47.
• Peng Q, et al. Dynamic immune landscape and VZV-specific T cell responses in patients with herpes zoster and postherpetic neuralgia. Front Immunol. 2022;13:887892. The study presents a comprehensive analysis of the immune cell profiles and dynamics in patients with PHN compared to those with herpes zoster.
48.
Liang X, Fan Y. Bidirectional two-sample Mendelian randomization analysis reveals a causal effect of interleukin-18 levels on postherpetic neuralgia risk. Front Immunol. 2023;14:1183378.PubMedPubMedCentralCrossRef
49.
Lin D, et al. Serum interleukin-6 levels are increased in post-herpetic neuralgia: a single-center retrospective study. An Bras Dermatol. 2023;98(2):202–7.PubMedPubMedCentralCrossRef
50.
Vanderwall AG, Milligan ED. Cytokines in pain: harnessing endogenous anti-inflammatory signaling for improved pain management. Front Immunol. 2019;10:3009.PubMedPubMedCentralCrossRef
51.
Xu Y, et al. Thymosin alpha-1 inhibits complete Freund’s adjuvant-induced pain and production of microglia-mediated pro-inflammatory cytokines in spinal cord. Neurosci Bull. 2019;35(4):637–48.PubMedPubMedCentralCrossRef
52.
Chu LW, et al. Loganin prevents chronic constriction injury-provoked neuropathic pain by reducing TNF-alpha/IL-1beta-mediated NF-kappaB activation and Schwann cell demyelination. Phytomedicine. 2020;67:153166.
53.
Fattori V, et al. Neuroimmune communication in infection and pain: friends or foes? Immunol Lett. 2021;229:32–43.PubMedCrossRef
54.
Leo M, et al. Modulation of voltage-gated sodium channels by activation of tumor necrosis factor receptor-1 and receptor-2 in small DRG neurons of rats. Mediators Inflamm. 2015;2015:124942.
55.
Cheng S, et al. Soluble tumor necrosis factor-alpha-induced hyperexcitability contributes to retinal ganglion cell apoptosis by enhancing Nav1.6 in experimental glaucoma. J Neuroinflammation. 2021;18(1)182.
56.
Zhang Q, Martin-Caraballo M, Hsia SV. Modulation of voltage-gated sodium channel activity in human dorsal root ganglion neurons by herpesvirus quiescent infection. J Virol. 2020;94(3).
57.
De Leon-Casasola OA, Mayoral Rojals V. The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence. J Pain Res. 2016;67.
58.
Wang A, et al. Randomized, placebo-controlled, multicenter clinical study on the efficacy and safety of lidocaine patches in chinese patients with postherpetic neuralgia. Dermatol Ther. 2023;13(7):1477–87.
59.
Castro-Junior CI. Role of calcium permeable channels in pain processing. Sine Loco: IntechOpen; 2018.
60.
Zhu Y, et al. P2X7 receptor antagonist BBG inhibits endoplasmic reticulum stress and pyroptosis to alleviate postherpetic neuralgia. Mol Cell Biochem. 2021;476(9):3461–8.PubMedCrossRef
61.
Zhang YY, et al. Activation of the N-methyl-D-aspartate receptor contributes to orofacial neuropathic and inflammatory allodynia by facilitating calcium-calmodulin-dependent protein kinase II phosphorylation in mice. Brain Res Bull. 2022;185:174–92.PubMedCrossRef
62.
Guimarães Pereira JE, et al. Efficacy and safety of ketamine in the treatment of neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. J Pain Res. 2022;15:1011–37.PubMedPubMedCentralCrossRef
63.
Iannone LF, et al. Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief. Temperature. 2023;10(1):50–66.CrossRef
64.
Tajti J, et al. Exploring novel therapeutic targets in the common pathogenic factors in migraine and neuropathic pain. Int J Mol Sci. 2023;24(4).
65.
Hou Q, et al. Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms. Pain. 2011;152(9):2036–51.PubMedPubMedCentralCrossRef
66.
Bubak AN, et al. Varicella zoster virus induces nuclear translocation of the neurokinin-1 receptor, promoting lamellipodia formation and viral spread in spinal astrocytes. J Infect Dis. 2018;218(8):1324–35.PubMedPubMedCentralCrossRef
67.
Suvas S. Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J Immunol. 2017;199(5):1543–52.PubMedCrossRef
68.
Yang Y, et al. Aprepitant inhibits JNK and p38/MAPK to attenuate inflammation and suppresses inflammatory pain. Front Pharmacol. 2021;12:811584.
69.
Kramer PR, et al. Lateral thalamic control of nociceptive response after whisker pad injection of varicella zoster virus. Neuroscience. 2017;356:207–16.PubMedCrossRef
70.
Hornung R, et al. Reduced activity of GAD67 expressing cells in the reticular thalamus enhance thalamic excitatory activity and varicella zoster virus associated pain. Neurosci Lett. 2020;736:135287.
71.
Kong CL, et al. Incidence rate of herpes zoster ophthalmicus: a retrospective cohort study from 1994 through 2018. Ophthalmology. 2020;127(3):324–30.PubMedCrossRef
72.
Alicino C, et al. Incidence of herpes zoster and post-herpetic neuralgia in Italy: results from a 3-years population-based study. Hum Vaccin Immunother. 2017;13(2):399–404.PubMedCrossRef
73.
Kim J, et al. Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. Korean J Pain. 2021;34(4):509–33.PubMedPubMedCentralCrossRef
74.
Schutzer-Weissmann J, Farquhar-Smith P. Post-herpetic neuralgia–a review of current management and future directions. Expert Opin Pharmacother. 2017;18(16):1739–50.PubMedCrossRef
75.
Wan CF, Song T. Comparison of two different pulsed radiofrequency modes for prevention of postherpetic neuralgia in elderly patients with acute/subacute trigeminal herpes zoster. Neuromodulation. 2022;25(8):1364–71.PubMedCrossRef
76.
Kang DH, et al. Earlier treatment improves the chances of complete relief from postherpetic neuralgia. Korean J Pain. 2017;30(3):214–9.
77.
Kato J, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160(5):1175–85.PubMedPubMedCentralCrossRef
78.
Robinson C, et al. A look at commonly utilized serotonin noradrenaline reuptake inhibitors (SNRIs) in chronic pain. Health Psychol Res. 2022;10(3):32309.PubMedPubMedCentral
79.
Gudin J, et al. Treatment patterns and medication use in patients with postherpetic neuralgia. J Manag Care Spec Pharm. 2019;25(12):1387–96.PubMed
80.
81.
Feller L, et al. Postherpetic neuralgia and trigeminal neuralgia. Pain Res Treat. 2017;2017.
82.
Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016;9:447–54.PubMedPubMedCentralCrossRef
83.
Kern KU, Schwickert-Nieswandt M. Postherpetic neuralgia of the left trigeminus nerve V1: successful therapy with capsaicin 8% patch. Schmerz. 2018;32(6):464–7.PubMedCrossRef
84.
Forstenpointner J, et al. Up-date on clinical management of postherpetic neuralgia and mechanism-based treatment: new options in therapy. J Infect Dis. 2018;218(suppl_2):S120–6.
85.
86.
Xiao L, et al. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med. 2010;11(12):1827–33.PubMedCrossRef
87.
88.
Allam AE, et al. Ultrasound-guided intervention for treatment of trigeminal neuralgia: an updated review of anatomy and techniques. Pain Res Manag. 2018;2018:5480728.PubMedPubMedCentralCrossRef
89.
Takechi K, et al. Real-time ultrasound-guided infraorbital nerve block to treat trigeminal neuralgia using a high concentration of tetracaine dissolved in bupivacaine. Scand J Pain. 2015;6(1):51–4.PubMedCrossRef
90.
Elawamy A, Abdalla EEM, Shehata GA. Effects of pulsed versus conventional versus combined radiofrequency for the treatment of trigeminal neuralgia: a prospective study. Pain Physician. 2017;20(6):E873–81.PubMed
91.
Li M, et al. The therapeutic efficacy of pulsed radiofrequency alone versus a dexamethasone and pulsed radiofrequency combination in patients with trigeminal postherpetic neuralgia: a double-blind, randomized controlled trial. Pain Physician. 2022;25(4):E543–9.
92.
Sinofsky A, Sharma T, Wright T. Stellate ganglion block for debilitating photophobia secondary to trigeminal, postherpetic neuralgia. Pain Pract. 2016;16(7):E99–102.
93.
Shanthanna H. Utility of stellate ganglion block in atypical facial pain: a case report and consideration of its possible mechanisms. Case Rep Med. 2013;2013:293826.
94.
Velasquez C, et al. Upper cervical spinal cord stimulation as an alternative treatment in trigeminal neuropathy. World Neurosurg. 2018;114:e641–6.PubMedCrossRef
95.
Chivukula S, et al. Cervical and cervicomedullary spinal cord stimulation for chronic pain: efficacy and outcomes. Clin Neurol Neurosurg. 2014;127:33–41.PubMedCrossRef
96.
Tomycz ND, Deibert CP, Moossy JJ. Cervicomedullary junction spinal cord stimulation for head and facial pain. Headache. 2011;51(3):418–25.PubMedCrossRef
97.
Deer TR, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the Neuromodulation Appropriateness Consensus Committee. Neuromodulation. 2014;17(6):515–50; discussion 550.
98.
Slavin K, et al. Trigeminal and occipital peripheral nerve stimulation for craniofacial pain. a single-institution experience and review of the literature. 2006;2006:21.
99.
Wan CF, Song T. Short-term peripheral nerve stimulation relieve pain for elder herpes zoster ophthalmicus patients: a retrospective study. Neuromodulation. 2021;24(6):1121–6.PubMedCrossRef
100.
Ellis JA, Mejia Munne JC, Winfree CJ. Trigeminal branch stimulation for the treatment of intractable craniofacial pain. J Neurosurg. 2015;123(1):283–8.
101.
Jakobs M, et al. Subcutaneous trigeminal nerve field stimulation for refractory trigeminal pain: a cohort analysis. Acta Neurochir. 2016;158:1767–74.PubMedCrossRef
102.
Hai Jun Shi ZQC. Correlation of serum inflammatory cytokine and immunoglobulin content with post-herpetic neuralgia in patients with acute herpes zoster. J Hainan Med Univ. 2017;23(1):97–100.
Metadata
Title
Trigeminal Postherpetic Neuralgia: From Pathophysiology to Treatment
Authors
Christy S. Niemeyer
Michael Harlander-Locke
Andrew N. Bubak
Rachael Rzasa-Lynn
Marius Birlea
Publication date
23-01-2024
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 4/2024
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-023-01209-z

Other articles of this Issue 4/2024

Current Pain and Headache Reports 4/2024 Go to the issue

Non-pharmacologic Aspects of Pain, Migraine, and Headache (D Buse, Section Editor)

Complementary and Integrative Medicine for the Treatment of Trigeminal Neuralgia and Trigeminal Autonomic Cephalalgia

Alternative Treatments for Pain Medicine (C Robinson, Section Editor)

Applications of Artificial Intelligence in Pain Medicine

Hot Topics in Pain and Headache (N Rosen, Section Editor)

Does weather trigger migraine?

Chronic Daily Headache (S-J Wang and S-P Chen, Section Editors)

Influences of Genetic and Environmental Factors on Chronic Migraine: A Narrative Review

Chronic Pain Medicine (O Viswanath, Section Editor)

The Gut Microbiota and Chronic Pain

Chronic Pain Medicine (O Viswanath, Section Editor)

Cervical Spinal Cord Stimulation: A Review
Image Credits